AlphaValue Reiterates “Reduce” Rating for AstraZeneca (AZN)
AstraZeneca (LON:AZN)‘s stock had its “reduce” rating reaffirmed by analysts at AlphaValue in a research report issued to clients and investors on Thursday, StockRatingsNetwork reports. They currently have a GBX 3,213 ($51.55) price target on the stock. AlphaValue’s price objective would indicate a potential upside of 3.21% from the company’s current price.
AZN has been the subject of a number of other recent research reports. Analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,620 ($58.08) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, October 1st. They now have a GBX 3,300 ($52.94) price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of AstraZeneca from GBX 50 ($0.80) to GBX 51 ($0.82) in a research note to investors on Monday, September 30th. They now have a “market perform” rating on the stock. Eleven research analysts have rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 3,104.21 ($49.80).
Shares of AstraZeneca (LON:AZN) traded up 0.64% on Thursday, hitting GBX 3133.00. 2,419,649 shares of the company’s stock traded hands. AstraZeneca has a 52-week low of GBX 2786.00 and a 52-week high of GBX 3544.50. The stock’s 50-day moving average is GBX 3215.42 and its 200-day moving average is GBX 3252.57. The company’s market cap is £39.225 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.